Neuroscience

Human brain
#Cell and gene therapy #Cell therapy #Gene therapy #Neurodegenerative disorders #Neuroscience

Five cell and gene therapy advances in neurodegeneration

Neurodegenerative diseases have recently increased at an alarming rate due to the ageing global population. There are a number of cell and gene therapies (CGTs) currently being developed to address these increasingly prevalent conditions. Diana Spencer provides an overview. A neurorestorative treatment Asklepios BioPharmaceutical’s (AskBio’s) AB-1005 is an adeno-associated virus… Read More

#Exclusive Content

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

This week in drug discovery (22-26 July) 

News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing… Read More

#News

Older adult receiving vaccine
#Dementia #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Shingles #University of Oxford

New shingles vaccine found to reduce risk of dementia

New evidence indicates that a new shingles vaccine is more protective against dementia compared to the previous shingles vaccine, which was also reported to reduce dementia rates. It is also more protective than vaccines against other infections. A study of more… Read More

#News

Cancer research
#Amyotrophic lateral sclerosis (ALS) #Neurology #Neuroscience #Phase II trial #TikoMed

‘Encouraging’ results for potential disease-modifying ALS drug

New clinical data have shown that TikoMed’s low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS). The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics… Read More

#Editor's Choice #News

Demyelination of neuron
#Amyotrophic lateral sclerosis (ALS) #Neurodegenerative disorders #Neuroscience #Partnership

New Scandinavian ALS drug research collaboration

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS). TikoMed has previously completed and reported on two successful Phase IIa clinical studies in ALS, one at… Read More

#News

Brain physiology
#Neuroscience #Newron Pharmaceuticals #Schizophrenia

Drug’s unique mechanism of action targets schizophrenia abnormalities

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS). The drug’s unique mechanism of action targets the core abnormalities in patients with schizophrenia and reduces hippocampal dopaminergic… Read More

#Editor's Choice #News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

DDW Highlights podcast expands to include vodcast 

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week has seen… Read More

#News

ALS concept
#Amyotrophic lateral sclerosis (ALS) #Biomarkers #Drug discovery #Neuroscience #Partnership

How a new partnership aims to tackle ALS

DDW Editor Reece Armstrong speaks to Alessio Travaglia, PhD, Director, Translational Science, Neuroscience, Foundation for the National Institutes of Health (FNIH) about challenges in treating amyotrophic lateral sclerosis (ALS) and why a new public-private partnership launched by the FNIH is hoping to advance new drugs and diagnostics for the disease.   RA:… Read More

#Exclusive Content

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

New DDW Highlights podcast: 1 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It is also available to watch as a vodcast:  This week… Read More

#News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

This week in drug discovery (24-28 June) 

News round-up for 24-28 June by DDW Senior Digital Content Editor Diana Spencer. This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as… Read More

#News

Neuroscience concept
#Drug discovery #In Focus Report #Market reporting #Neuroscience

New eReport: Advances in neuroscience research

The global prevalence of dementia is approximately 24 million, and is predicted to double every 20 years until at least 2040. Currently, no medications can cure this, though 2024 has proved to be a poignant year of developments in neuroscience, especially considering the challenges faced in previous decades. This guide… Read More

#News

Drug Discovery World report on Neuroscience
#Drug discovery #In Focus Report #Market reporting #Neuroscience

Neuroscience: Advances in research and opportunities ahead

Download this In Focus eReport to learn more about the drug discovery innovation and advancement taking place in this field. The eReport includes: A global market overview including prevalence, value and future outlook A scientific article on developing therapeutics targeting biomolecular condensates An interview with ApconiX’s Director and Co-founder, Professor… Read More

#DDW eBooks #DDW In Focus eReports #Intelligence

Neuroscience Parkinson's disease
#Bayer #Biogen #BlueRock Therapeutics #Cell therapy #Ionis Pharmaceuticals #Mission Therapeutics #Neuroscience #Parkinson's #Small molecul #Stem cells #Vaxxinity #Vesper Bio

Exploring new frontiers in Parkinson’s Disease   

With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW's Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition.  Parkinson’s is the most common movement disorder, affecting around… Read More

#Exclusive Content #Trends & Analysis

Neurons in a brain with Alzheimer's disease
#Alchemab Therapeutics #Funding #Neuroscience #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

Novel antibody with potential in Parkinson’s disease  

Alchemab Therapeutics has been awarded a grant of $595,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease (PD) programme.  The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in PD, a potentially unique… Read More

#News